DUBLIN–(BUSINESS WIRE)–The “TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions – Global Forecast up to 2025” report has been added to ResearchAndMarkets.com’s offering.

Overview of the Global TNF Alpha Inhibitors Market Research:

The author’s market research report predicts that the global TNF alpha inhibitors market will grow at a CAGR of 3.6% during the forecast period 2019-2025.

TNF inhibitors, also known as TNF blockers, anti-TNF drugs, and biologic therapies, are a cluster of medications used to treat inflammatory conditions, including rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (Crohn’s and ulcerative colitis), and psoriasis. The drugs decrease inflammation and can stop disease development by targeting an inflammation-causing substance, tumor necrosis factor (TNF).

The market is witnessing the loss of patents in Europe for various blockbuster drugs, resulting in the emergence of biosimilars. In April 2019, Eticovo – a biosimilar from Samsung Bioepis to Amgen’s Enbrel (etanercept), received FDA approval. In November 2018, FDA approved Hyrimoz developed by Sandoz, a biosimilar to AbbVie’s blockbuster drug Humira, which will be launched in the US market by 2023. Currently, only five approved TNF inhibitors, i.e., adalimumab, certolizumab, etanercept, golimumab, and infliximab, control the market. The wide application of these drugs for numerous autoimmune diseases ensures constant growth of the market during the forecast period 2019-2025.

According to the author analysis, North America accounted for the largest share of the global TNF alpha inhibitors market in 2018 and will retain a high position during the forecast period. North America is followed by Europe, with a market share of more than 20% in 2018.

In 2018, the adalimumab segment accounted for the largest share and is expected to grow at a mid-single-digit CAGR during the forecast period. Increased clinical efficacy and high preference by physicians for the treatment of severe rheumatic diseases made the segment the largest shareholder in 2018. Golimumab is expected to grow at a high CAGR during the forecast period 2019-2025.

Many companies are making huge investments to develop products and enter the market as soon as biologics lose their patents. Among various TNF alpha inhibitors, adalimumab has the highest number of ongoing clinical trials, followed by certolizumab pegol.

Global TNF Alpha Inhibitors Market Research Competitive Analysis: The market is growing at a steady rate, i.e., at a CAGR of 3.6% during the forecast period 2019-2025. New drug launches, product approvals, strategic partnerships, and collaborations are among the significant strategies adopted by market leaders to maintain their leadership position. For instance, in July 2019, the US FDA approved HADLIMA by Samsung Bioepis, a biosimilar referencing HUMIRA, to treat juvenile idiopathic arthritis, adult Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, rheumatoid arthritis, and plaque psoriasis. In March 2019, the US FDA approved Cimzia injection to treat non-radiographic axial spondyloarthritis (nr-axSpA) in adults, with detached signs of swelling making it the first-ever FDA approved treatment fulfilling the unmet needs for nr-axSpA; and in May 2018, the drug was approved for the treatment of moderate-to-severe plaque psoriasis.

The rising incidence of chronic autoimmune diseases has led to the increasing launch of biosimilars globally. In May 2019, Fresenius Kabi launched biosimilar adalimumab IDACIO in Germany. In May 2019, Janssen launched Simponi Autoinjector in Japan, and the drugs are distributed by Mitsubishi Tanabe. In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new drugs to obtain a high share in the market.

Key Competitive Facts:

• UCB Biopharma S.P.R.L. is conducting a phase 3 clinical trial in 15 centers in Germany to study Efficacy and safety of certolizumab pegol (CZP) versus active comparator and placebo in subjects with Plaque Psoriasis (PSO) (CIMPACT).
• Globally, over 95% of the clinical trials of certolizumab are conducted by UCB Pharma.
• In July 2018, Mylan made a patent license agreement with AbbVie over Mylan’s proposed Humira biosimilar. Under the terms of the agreement, AbbVie will grant Mylan exclusive licenses on Humira’s intellectual properties on July 31, 2023 in the US and other countries excluding Europe.

Key Topics Covered:

1 Industry Outlook

1.1 Industry Overview

1.1.1 Global Driver for Pharmaceutical Demand

1.1.2 R&D Pipeline in Pharmaceutical Industry

1.1.3 Top Pharma Drugs by Sales ($Million)

1.2 Industry Trends

1.3 Total Addressable Market

1.4 Trends of the Immunotherapy Drugs Market

2 Report Outline

2.1 Report Scope

2.2 Report Summary

2.3 Research Methodology

2.4 Report Assumptions

3 Market Snapshot

3.1 Market Definition – Infoholic Research

3.2 Segmented Addressable Market (SAM)

3.3 Trends of the TNF Alpha Inhibitors Market

3.4 Related Markets

3.4.1 Oncology Drugs

3.4.2 Biologics

3.4.3 Biosimilars

4 Market Outlook

4.1 Market Segmentation

4.2 PEST Analysis

4.3 Porter 5(Five) Forces

5 Market Characteristics

5.1 DRO – Global TNF Alpha Inhibitors Market Dynamics

5.1.1 Drivers

5.1.1.1 Increasing prevalence of chronic autoimmune disease

5.1.1.2 Constant research to develop target-based biologics

5.1.2 Opportunities

5.1.2.1 Continuous development of biosimilars

5.1.2.2 Increasing opportunities in the emerging market

5.1.3 Restraints

5.1.3.1 Complex drug development process

5.1.3.2 Patent expiry

5.2 DRO – Impact Analysis

5.3 Key Stakeholders

6 Product: Market Size and Analysis

6.1 Overview

6.2 Adalimumab

6.3 Certolizumab Pegol

6.4 Etanercept

6.5 Golimumab

6.6 Infliximab

7 Pipeline Analysis: Market Size and Analysis

7.1 Overview

7.2 Phase I

7.3 Phase II

7.4 Phase III

8 Regions: Market Size and Analysis

8.1 Overview

8.2 North America

8.3 Europe

8.4 Asia Pacific

8.5 Rest of the World

8.5.2 Mexico

8.5.3 Brazil

8.5.4 Middle East and Africa

9 Competitive Landscape

10 Vendors Profile

10.1 AbbVie Inc.

10.1.1 Overview

10.1.2 Geographic Revenue

10.1.3 Business Focus

10.1.4 SWOT Analysis

10.1.5 Business Strategies

10.2 Novartis AG

10.3 Amgen Inc.

10.4 Johnson & Johnson

10.5 Celgene Corporation

11 Companies to Watch For

11.1 Apogenix

11.1.1 Overview

11.2 Celltrion Healthcare

11.3 Samsung Bioepis Co. Ltd.

11.4 3SBio Inc.

11.5 Shanghai CP Guojian Pharmaceutical Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/azvd3a

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions – Global Forecast up to 2025” report has been added to ResearchAndMarkets.com’s offering.

Overview of the Global TNF Alpha Inhibitors Market Research:

The author’s market research report predicts that the global TNF alpha inhibitors market will grow at a CAGR of 3.6% during the forecast period 2019-2025.

TNF inhibitors, also known as TNF blockers, anti-TNF drugs, and biologic therapies, are a cluster of medications used to treat inflammatory conditions, including rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (Crohn’s and ulcerative colitis), and psoriasis. The drugs decrease inflammation and can stop disease development by targeting an inflammation-causing substance, tumor necrosis factor (TNF).

The market is witnessing the loss of patents in Europe for various blockbuster drugs, resulting in the emergence of biosimilars. In April 2019, Eticovo – a biosimilar from Samsung Bioepis to Amgen’s Enbrel (etanercept), received FDA approval. In November 2018, FDA approved Hyrimoz developed by Sandoz, a biosimilar to AbbVie’s blockbuster drug Humira, which will be launched in the US market by 2023. Currently, only five approved TNF inhibitors, i.e., adalimumab, certolizumab, etanercept, golimumab, and infliximab, control the market. The wide application of these drugs for numerous autoimmune diseases ensures constant growth of the market during the forecast period 2019-2025.

According to the author analysis, North America accounted for the largest share of the global TNF alpha inhibitors market in 2018 and will retain a high position during the forecast period. North America is followed by Europe, with a market share of more than 20% in 2018.

In 2018, the adalimumab segment accounted for the largest share and is expected to grow at a mid-single-digit CAGR during the forecast period. Increased clinical efficacy and high preference by physicians for the treatment of severe rheumatic diseases made the segment the largest shareholder in 2018. Golimumab is expected to grow at a high CAGR during the forecast period 2019-2025.

Many companies are making huge investments to develop products and enter the market as soon as biologics lose their patents. Among various TNF alpha inhibitors, adalimumab has the highest number of ongoing clinical trials, followed by certolizumab pegol.

Global TNF Alpha Inhibitors Market Research Competitive Analysis: The market is growing at a steady rate, i.e., at a CAGR of 3.6% during the forecast period 2019-2025. New drug launches, product approvals, strategic partnerships, and collaborations are among the significant strategies adopted by market leaders to maintain their leadership position. For instance, in July 2019, the US FDA approved HADLIMA by Samsung Bioepis, a biosimilar referencing HUMIRA, to treat juvenile idiopathic arthritis, adult Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, rheumatoid arthritis, and plaque psoriasis. In March 2019, the US FDA approved Cimzia injection to treat non-radiographic axial spondyloarthritis (nr-axSpA) in adults, with detached signs of swelling making it the first-ever FDA approved treatment fulfilling the unmet needs for nr-axSpA; and in May 2018, the drug was approved for the treatment of moderate-to-severe plaque psoriasis.

The rising incidence of chronic autoimmune diseases has led to the increasing launch of biosimilars globally. In May 2019, Fresenius Kabi launched biosimilar adalimumab IDACIO in Germany. In May 2019, Janssen launched Simponi Autoinjector in Japan, and the drugs are distributed by Mitsubishi Tanabe. In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new drugs to obtain a high share in the market.

Key Competitive Facts:

• UCB Biopharma S.P.R.L. is conducting a phase 3 clinical trial in 15 centers in Germany to study Efficacy and safety of certolizumab pegol (CZP) versus active comparator and placebo in subjects with Plaque Psoriasis (PSO) (CIMPACT).
• Globally, over 95% of the clinical trials of certolizumab are conducted by UCB Pharma.
• In July 2018, Mylan made a patent license agreement with AbbVie over Mylan’s proposed Humira biosimilar. Under the terms of the agreement, AbbVie will grant Mylan exclusive licenses on Humira’s intellectual properties on July 31, 2023 in the US and other countries excluding Europe.

Key Topics Covered:

1 Industry Outlook

1.1 Industry Overview

1.1.1 Global Driver for Pharmaceutical Demand

1.1.2 R&D Pipeline in Pharmaceutical Industry

1.1.3 Top Pharma Drugs by Sales ($Million)

1.2 Industry Trends

1.3 Total Addressable Market

1.4 Trends of the Immunotherapy Drugs Market

2 Report Outline

2.1 Report Scope

2.2 Report Summary

2.3 Research Methodology

2.4 Report Assumptions

3 Market Snapshot

3.1 Market Definition – Infoholic Research

3.2 Segmented Addressable Market (SAM)

3.3 Trends of the TNF Alpha Inhibitors Market

3.4 Related Markets

3.4.1 Oncology Drugs

3.4.2 Biologics

3.4.3 Biosimilars

4 Market Outlook

4.1 Market Segmentation

4.2 PEST Analysis

4.3 Porter 5(Five) Forces

5 Market Characteristics

5.1 DRO – Global TNF Alpha Inhibitors Market Dynamics

5.1.1 Drivers

5.1.1.1 Increasing prevalence of chronic autoimmune disease

5.1.1.2 Constant research to develop target-based biologics

5.1.2 Opportunities

5.1.2.1 Continuous development of biosimilars

5.1.2.2 Increasing opportunities in the emerging market

5.1.3 Restraints

5.1.3.1 Complex drug development process

5.1.3.2 Patent expiry

5.2 DRO – Impact Analysis

5.3 Key Stakeholders

6 Product: Market Size and Analysis

6.1 Overview

6.2 Adalimumab

6.3 Certolizumab Pegol

6.4 Etanercept

6.5 Golimumab

6.6 Infliximab

7 Pipeline Analysis: Market Size and Analysis

7.1 Overview

7.2 Phase I

7.3 Phase II

7.4 Phase III

8 Regions: Market Size and Analysis

8.1 Overview

8.2 North America

8.3 Europe

8.4 Asia Pacific

8.5 Rest of the World

8.5.2 Mexico

8.5.3 Brazil

8.5.4 Middle East and Africa

9 Competitive Landscape

10 Vendors Profile

10.1 AbbVie Inc.

10.1.1 Overview

10.1.2 Geographic Revenue

10.1.3 Business Focus

10.1.4 SWOT Analysis

10.1.5 Business Strategies

10.2 Novartis AG

10.3 Amgen Inc.

10.4 Johnson & Johnson

10.5 Celgene Corporation

11 Companies to Watch For

11.1 Apogenix

11.1.1 Overview

11.2 Celltrion Healthcare

11.3 Samsung Bioepis Co. Ltd.

11.4 3SBio Inc.

11.5 Shanghai CP Guojian Pharmaceutical Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/azvd3a

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900